Published online Aug 15, 2023. doi: 10.4239/wjd.v14.i8.1271
Peer-review started: May 31, 2023
First decision: June 14, 2023
Revised: June 19, 2023
Accepted: July 14, 2023
Article in press: July 14, 2023
Published online: August 15, 2023
Processing time: 72 Days and 8.8 Hours
China has a high prevalence of diabetes and a large base of diabetes. Diabetic retinopathy (DR) seriously affects the patients’ quality of life.
DR is an important condition affecting people’s lives, health, and economic development. Therefore, effective and efficient treatment programs are required.
To provide better treatment for DR with macular edema.
We selected 130 patients with diabetic macular edema who were hospitalized between January 2018 and May 2020 and assigned them to the following two groups according to treatment: the observation and control groups. The control group was treated with laser photocoagulation, and the observation group received laser photocoagulation with an intravitreal injection of conbercept (65 patients in each group). Clinical efficacy was evaluated, and seven indicators were measured.
The total efficacy rate in the observation group (93.85%) was higher than that in the control group (78.46%). In both groups, the BCVA correction effect was better after treatment, and that in the observation group was superior to that in the control group. Retinal thickness and CMT improved after treatment, and the observation group was superior to the control group. The levels of VEGF, IL-6, sICAM-1, and BFGF in both groups improved after treatment, and the observation group was superior to the control group.
In patients with macular edema, the combination of laser photocoagulation and intravitreal injections of Conbercept for DME is a more effective and safer way to improve vision, reduce retinal thickness, and lower intraocular cytokine VEGF levels.
It is more effective in treating DR with macular edema and is worthy of widespread promotion.